Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 7/20 | 0.38 |
| ▸ | HTR2A | P28223 | 7/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | GCGR | P47871 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1750783 | 0.90 | REN (0.35) | RENCYP3A4KCNH2 | |
| SCHEMBL3095965 | 0.84 | LPAR1 (0.34) | — | |
| SCHEMBL3075616 | 0.84 | HTR2C (0.39) | HTR2A | |
| SCHEMBL1751560 | 0.84 | REN (0.40) | RENHTR2ANR1H4HSD11B1GCGR | |
| SCHEMBL3079714 | 0.82 | HDAC3 (0.38) | CYP3A4 | |
| SCHEMBL1752126 | 0.81 | REN (0.43) | RENHTR2AHSD11B1CYP3A4KCNH2 | |
| SCHEMBL1751218 | 0.80 | SSTR4 (0.35) | — | |
| SCHEMBL1751081 | 0.80 | REN (0.42) | RENHTR2ANR1H4HSD11B1GCGR | |
| SCHEMBL1750843 | 0.79 | LPAR1 (0.35) | — | |
| SCHEMBL1751809 | 0.79 | REN (0.45) | RENCYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968720-B2 | Secondary amines as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-06-28 | — | — | US | disclosed |
| US-20100324052-A1 | NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES | BEZENCON OLIVIER | 2010-12-23 | — | — | US | disclosed |
| US-7799805-B2 | Piperidine carboxylic acid amide derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-21 | — | — | US | disclosed |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-07-09 | — | — | US | disclosed |
| EP-1981847-A1 | SECONDARY AMINES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-20080214598-A1 | Novel Piperidine Carboxylic Acid Amide Derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2008-09-04 | — | — | US | disclosed |
| WO-2007088514-A1 | SECONDARY AMINES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214598-A1 | Novel Piperidine Carboxylic Acid Amide Derivatives | REN, ACE, AGTR2 | REN 1/4885HTR2A 2555/4885NR1H4 1272/4885 |
| US-20100324052-A1 | NOVEL PIPERIDINE CARBOXYLIC ACID AMINE DERIVATIVES | REN, ACE, AGTR2 | REN 1/4885HTR2A 1616/4885NR1H4 1151/4885 |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | REN, ACE, AGTR1 | REN 1/4885HTR2A 860/4885NR1H4 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.